

PEER-REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 67328

Title: COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A Systematic Review

Reviewer's code: 05467044 Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Italy

Manuscript submission date: 2021-04-21

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-13 08:42

Reviewer performed review: 2021-05-14 03:40

Review time: 18 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No



https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Comments on the manuscript entitled "COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A Systematic Review" COVID-19 (SARS-CoV-2 infection) is a worldwide medical emergency and represents a major threat for several patient populations. Nevertheless, reports about the prevalence of hematologic malignancies especially lymphoma are very limited. So the authors systematically reviewed the current literature reporting on SARS-CoV-2 infection in lymphoma patients and focused on several factors including prognostic index, disease course. However, there are several minor problems shown as follows suggested revised: 1 The data such as the efficacy (whether remission) of patients with lymphoma when they are infected COVID-19 should be added. 2 The format of Conclusions should be rearranged and there are too many paragraphs.



PEER-REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 67328

Title: COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A Systematic Review

Reviewer's code: 05274507 Position: Editorial Board

Academic degree: BHMS, PhD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Italy

Manuscript submission date: 2021-04-21

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-14 08:56

Reviewer performed review: 2021-05-18 11:52

Review time: 4 Days and 2 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No



SPECIFIC COMMENTS TO AUTHORS

1.This is an excellent article. Thanks to the authors for this review and the contributions of many researchers. 2.English writing should be polished. Several highlighted areas should be corrected. For example, "cencer' in page 9. 3.Abbreviations in the context should be consistent, for example: SARS-CoV2 and Sars-CoV2. 4.What's the meaning of paragraph: Lymphoma patients are at high risk of infections? Maybe you can put it in INTRDUCTION or DISCUSSION. 5.Page 9, the presence of active disease was a strong predictor of death. This sentence can be included in the conclusion of the article.



PEER-REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 67328

Title: COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A Systematic Review

Reviewer's code: 05729685
Position: Peer Reviewer
Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: Italy

Manuscript submission date: 2021-04-21

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-13 08:44

Reviewer performed review: 2021-05-21 13:27

Review time: 8 Days and 4 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No



https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

In this review, the authors summarized recent reports of COVID-19 in lymphoma patients. This manuscript is well documented and organized. Since the authors stated that "We also highlighted the potential differences in COVID-19 clinical picture according to lymphoma subtype" in the Abstract, more attention to this point would be welcome to improve the manuscript (eg. Are there any differences of the clinical courses between PTCL and B-cell lymphoma?). Also, it would be better to describe the potential effects of immune check point inhibitors on the clinical course if such reports have been published.